门静脉高压症:经颈静脉肝内门体分流术的合理应用及其相关并发症的预防和处理*

doi:10.3969/j.issn.1672-5069.2023.01.002

摘要/Abstract

Key words: Portal hypertension, Hepatic venous pressure gradient, Transjugular intrahepatic portosystemic shunt, Complications, Prevention

赖瑞敏, 朱月永. 门静脉高压症:经颈静脉肝内门体分流术的合理应用及其相关并发症的预防和处理^*[J]. 实用肝脏病杂志, 2023, 26(1): 4-7.

Lai Ruimin, Zhu Yuejiu. Portal hypertension: indication of transjugular intrahepatic portosystemic shunt and the prevention of related complications[J]. Journal of Practical Hepatology, 2023, 26(1): 4-7.

参考文献

[1] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Mayo Clin Proc, 2019, 94(4): 714-726.
[2] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[3] Richter GM, Palmaz JC, Nöldge G, et al. The transjugular intrahepatic portosystemic stent-shunt. A new nonsurgical percutaneous method. Der Radiologe, 1989, 29(8): 406-411.
[4] Yin X, Gu L, Zhang M, et al. Covered TIPS procedure-related major complications: incidence, management and outcome from a single center. Front Med (Lausanne), 2022, 9: 834106.
[5] Garcia-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol, 2013, 58(1): 45-50.
[6] García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med, 2010, 362(25): 2370-2379.
[7] Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology (Baltimore, Md), 2004, 40(4): 793-801.
[8] Palaniyappan N, Cox E, Bradley C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol, 2016, 65(6): 1131-1139.
[9] Pons M, Augustin S, Scheiner B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gstroenterol, 2021, 116(4): 723-732.
[10] 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南. 中华肝脏病杂志, 2019, 27(8): 582-593.
[11] Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet (London, England), 2003, 361(9361): 952-954.
[12] 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管,胃底静脉曲张破裂出血诊治专家共识(2019年版). 中国消化外科杂志, 2019, 18(12): 1087-1093.
[13] Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology (Baltimore, Md), 2017, 66(4): 1219-1231.
[14] Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut, 2018, 67(12): 2156-2168.
[15] Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md), 2016, 63(2): 581-589.
[16] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md), 2017, 65(1): 310-335.
[17] Hernández-Gea V, Procopet B, Giráldez Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study. Hepatology (Baltimore, Md), 2019, 69(1): 282-293.
[18] Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent Ascites. Gastroenterology, 2017, 152(1): 157-163.
[19] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[20] Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut, 2010, 59(7): 988-1000.
[21] Larrue H, Vinel JP, Bureau C. Management of severe and refractory ascites. Clin Liver Dis, 2021, 25(2): 431-440.
[22] Hewett LJ, Bradshaw ML, Gordon LL, et al. Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy. Hepatology (Baltimore, Md), 2016, 64(4): 1364-1366.
[23] Banini BA, Alwatari Y, Stovall M, et al. Multidisciplinary management of hepatic hydrothorax in 2020: an evidence-based review and guidance. Hepatology (Baltimore, Md), 2020, 72(5): 1851-1863.
[24] Song T, Rössle M, He F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis, 2018, 50(4): 323-330.
[25] Guerrini GP, Pleguezuelo M, Maimone S, et al. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant, 2009, 9(1): 192-200.
[26] Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol, 2018, 16(2): 162-177,e1.
[27] Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int, 2021, 15(3): 531-567.
[28] Saad WE, Darwish WM, Davies MG, et al. Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol, 2010, 21(10): 1512-1520.
[29] Tripathi D, Macnicholas R, Kothari C, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther, 2014, 39(8): 864-872.
[30] Sun Y, Ma X, Feng L, Guan S, et al. Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome. Gut, 2012, 61(12): 1779-1780.
[31] Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis, 2012, 13(1): 33-39.
[32] Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis, 2011, 43(7): 503-514.
[33] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017, 33(9): 1627-1637.
[34] Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
[35] Violi F, Corazza GR, Caldwell SH, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb Haemost, 2019, 119(3): 496-499.
[36] Fagiuoli S, Bruno R, Debernardi Venon W, et al. Consensus conference on TIPS management: Techniques, indications, contraindications. Dig Liver Dis, 2017, 49(2): 121-137.
[37] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
[38] Chamarthy MR, Anderson ME, Pillai AK, et al. Thrombolysis and transjugular intrahepatic portosystemic shunt creation for acute and subacute portal vein thrombosis. Tech Vasc Interv Radiol, 2016, 19(1): 42-51.
[39] Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci, 2007, 52(11): 3290-3295.
[40] Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, Md), 1999, 29(1): 62-67.

门静脉高压症:经颈静脉肝内门体分流术的合理应用及其相关并发症的预防和处理^*

Portal hypertension: indication of transjugular intrahepatic portosystemic shunt and the prevention of related complications

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄晓铨, 陈世耀. 重视规范化处理门静脉高压并发食管胃静脉曲张出血^*[J]. 实用肝脏病杂志, 2023, 26(1): 1-3.
[2]	许青, 杨健, 宗金娟. 特发性非肝硬化门静脉高压症患者肝脏影像学和病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 91-94.
[3]	孙静, 张伟伟, 马智勇, 代树本, 邓彦东. 经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗乙型肝炎肝硬化并发食管胃静脉曲张患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 853-856.
[4]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[5]	贺伟, 刘贤国, 王刚, 卢建利, 叶智. 根治性手术治疗不同Child-Pugh分级的肝泡型包虫病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(3): 435-438.
[6]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[7]	何翼彪, 王智鹏, 白磊. 三维可视化系统联合纤维胆道镜治疗肝胆管结石患者近期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 287-290.
[8]	陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.
[9]	姜晓颖, 杨恒, 李明武, 袁保东, 田明, 徐金田, 梅早仙, 潘洪秋, 刘向, 陈晓红, 于德美, 李成俊, 高绪胜, 刘旭晖, 刘建峰, 金龙, 王均琴, 李亮. 甘草酸二铵肠溶胶囊预防初治的肺结核患者药物性肝损害有效性研究[J]. 实用肝脏病杂志, 2022, 25(1): 62-65.
[10]	赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展[J]. 实用肝脏病杂志, 2021, 24(5): 613-616.
[11]	李伟之, 李培杰, 马富权, 刘梦莹, 薛挥. 应用利伐沙班抗凝治疗经皮血管内介入治疗的布加综合征患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 621-624.
[12]	李伟, 宋卫东, 谢巴图白音. 采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 629-632.
[13]	史海军, 张日欣, 宁纯民. 规则性肝叶切除治疗复杂性肝内胆管结石患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(4): 585-588.
[14]	孙若楠, 张春清. 食管胃底静脉曲张破裂出血预防和治疗进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 607-610.
[15]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.